natgillin/translations-raw huggingface dataset:
• does not make enough insulin to control the level of sugar in your blood or 
• da proizvede dovolj insulina za zadostno uravnavanje koncentracije krvnega sladkorja ali • da pravilno izkoristi v telesu nastali insulin.
Thyroid adverse events, such as goitre have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, and in particular in patients with pre-existing thyroid disease. 
V kliničnih preskušanjih agonistov receptorjev GLP-1, vključno z liraglutidom, so poročali o pojavu ščitničnih neželenih učinkov, kot je golšavost, in sicer še posebej pri bolnikih z že obstoječo boleznijo ščitnice.
Figure 2 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or in combination with metformin 
Slika 2: Povprečna vrednost HbA1c (%) po tednih zdravljenja pri bolnikih z nezadostno urejeno sladkorno boleznijo tipa 2 pri zdravljenju s sulfonilsečnino, samo ali v kombinaciji z metforminom
Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide. 
atorvastatina zmanjšala za 38 %, mediani čas do največje koncentracije (tmax) pa z 1 ure podaljšal na 3 ure.
No studies have been performed with Xultophy in children and adolescents below 18 years of age. 
Pri otrocih in mladostnikih, mlajših od 18 let, študij z zdravilom Xultophy niso izvedli.
Headache, slurred speech, fast heartbeat, cold sweat, cool pale skin, feeling sick (nausea), feeling very hungry, shaking, feeling nervous or worried, unusually tired, weak and sleepy or confused, difficulty concentrating, short-lasting changes in your sight. 
Opozorilni znaki prenizkega krvnega sladkorja - lahko se pojavijo nenadoma Glavobol, nerazločno govorjenje, hitro bitje srca, hladno znojenje, hladna in bleda koža, siljenje na bruhanje, huda lakota, tresenje, živčnost ali zaskrbljenost, nenavadna utrujenost, oslabelost in zaspanost ali zmedenost, težave s koncentracijo, kratkotrajne motnje vida.
• Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. 
• Hude hipoglikemije, ko bolnik ne more ukrepati sam, se lahko zdravi z glukagonom (0,5 do
In vitro data suggest that the potential for pharmacokinetic drug interactions related to CYP interaction and protein binding is low for both liraglutide and insulin degludec. 
Farmakokinetične interakcije In vitro podatki kažejo, da je potencial liraglutida in insulina degludek za farmakokinetične interakcije,
This may lead to high blood sugar level. 
Ukrepanje v primeru previsokega krvnega sladkorja
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 291) for Xultophy and 0.00 (0 patients out of 199) for GLP-1 receptor agonists. 
Delež hude hipoglikemije na bolnikov-let izpostavljenosti (odstotek bolnikov) je bil pri zdravilu Xultophy 0,01 (1 od 291 bolnikov), pri agonistih receptorjev GLP-1 pa 0,00 (0 od 199 bolnikov).
Store in a refrigerator 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku.
Inflammatory bowel disease and diabetic gastroparesis There is no experience with Xultophy in patients with inflammatory bowel disease and diabetic gastroparesis. 
Vnetna črevesna bolezen in diabetična gastropareza Pri bolnikih s kronično vnetno črevesno boleznijo in z diabetično gastroparezo ni izkušenj z uporabo zdravila Xultophy, zato uporaba zdravila Xultophy pri teh bolnikih ni priporočljiva.
Therapy with GLP-1 receptor agonists should be discontinued prior to initiation of Xultophy. 
Prehod z zdravljenja z agonistom receptorjev GLP-1 Pred uvedbo zdravljenja z zdravilom Xultophy je treba zdravljenje z agonistom receptorjev GLP-1
High blood sugar may happen if you: 
Previsok krvni sladkor se lahko pojavi, če:
Component of a multipack, can't be sold separately 
Ni za ločeno prodajo.
In all trials, the starting dose was given according to label and a twice-weekly titration regimen for Xultophy was used (see Table 2). 
Xultophy je bila uporabljena shema titriranja dvakrat na teden (glejte preglednico 2).
Conversely, during hypoglycaemia liraglutide diminishes insulin secretion and does not impair glucagon secretion. 
Nasprotno pa liraglutid med hipoglikemijo zmanjša izločanje insulina, ne vpliva pa na izločanje glukagona.
• The pen scale shows you approximately how much solution is left in your pen. 
• Merilo preostanka prikazuje koliko je približno še ostalo raztopine v injekcijskem peresniku.
Dosing time 
Čas odmerjanja
This is because improvement in your blood sugar may not happen straight away. 
Meritev boste morda morali ponoviti večkrat, saj se koncentracija krvnega sladkorja morda ne bo takoj zvečala.
Figure 3 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on GLP-1 receptor agonists 
Slika 3: Povprečna vrednost HbA1c (%) po tednih zdravljenja pri bolnikih z nezadostno urejeno sladkorno boleznijo tipa 2 pri zdravljenju z agonisti receptorjev GLP-1
The percentage of patients experiencing severe or blood-glucose confirmed symptomatic hypoglycaemia was 19.8% in the Xultophy group and 52.6% in the basal-bolus insulin group, and the estimated rate ratio was 0.11 [95% CI: 0.08-0.17]. 
je bil 19,8 % v skupini z zdravilom Xultophy in 52,6 % v skupini z bazalno-bolusnima insulinoma; ocenjeno razmerje pojavnosti je bilo 0,11 [95 % IZ: 0,08-0,17].
Liraglutide is metabolised in a similar manner to large proteins without a specific organ having been identified as major route of elimination. 
Liraglutid se presnavlja na podoben način kot velike beljakovine.
Therapy with basal insulin should be discontinued prior to initiation of Xultophy. 
Pred uvedbo zdravljenja z zdravilom Xultophy je treba zdravljenje z bazalnim insulinom ukiniti.
Each unused pre-filled pen (3 mL) contains 300 units of insulin degludec and 10.8 mg liraglutide. 
En nov napolnjen injekcijski peresnik (3 ml) vsebuje 300 enot insulina degludek in 10,8 mg liraglutida.
Due to the liraglutide component, Xultophy is not recommended for use in patients with severe hepatic impairment (see section 5.2). 
Zaradi sestavine liraglutid uporaba zdravila Xultophy ni priporočljiva pri bolnikih s hudo okvaro jeter
In three trials with patients inadequately controlled on basal insulin, systolic blood pressure was reduced by 5.4 mmHg with Xultophy and 1.7 mmHg with insulin degludec, with a statistically significant estimated treatment difference of -3.71 mmHg (p=0.0028), reduced by 3.7 mmHg with Xultophy vs 0.2 mmHg with insulin glargine, with a statistically significant estimated treatment difference of -3.57 mmHg (p<0.001) and reduced by 4.5 mmHg with Xultophy vs 1.16 mmHg with insulin glargine U100 plus insulin aspart, with a statistically significant estimated treatment difference of -3.70 mmHg (p=0.0003). 
V treh preskušanjih, izvedenih pri bolnikih z nezadostno urejeno glikemijo pri zdravljenju z bazalnim insulinom, se je v enem preskušanju vrednost sistoličnega krvnega tlaka pri uporabi zdravila Xultophy zmanjšala za 5,4 mmHg, pri uporabi insulina degludek pa za 1,7 mmHg, s statistično značilno ocenjeno razliko zdravljenja -3,71 mmHg (p=0,0028).
Glucose monitoring is to be intensified and the dose adjusted on an individual basis. 
Koncentracijo glukoze v krvi je treba spremljati pozorneje ter odmerek prilagoditi potrebam posameznega bolnika.
Gender had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis. 
Rezultati analize populacijske farmakokinetike kažejo, da spol nima klinično pomembnega vpliva na farmakokinetiko zdravila Xultophy.
The key results of the trial are listed in Figure 5 and Table 5. 
Ključni rezultati preskušanja so prikazani na sliki 5 in v preglednici 5.
Approx. how much solution is left 
približna količina preostale raztopine
Non-clinical safety data revealed no safety concern for humans based on repeated dose toxicity studies. 
Neklinični podatki na osnovi študij toksičnosti pri ponavljajočih se odmerkih ne kažejo posebnega tveganja za človeka.
One pre-filled pen contains 300 units insulin degludec and 10.8 mg liraglutide in 3 mL solution 1 mL solution contains 100 units of insulin degludec and 3.6 mg liraglutide One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide 
En ml raztopine vsebuje 100 enot insulina degludek in 3,6 mg liraglutida, En odmerni korak vsebuje 1 enoto insulina degludek in 0,036 mg liraglutida.
Xultophy is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. 
Zdravilo Xultophy je namenjeno zdravljenju odraslih z neustrezno nadzorovano sladkorno boleznijo tipa 2, in sicer za izboljšanje urejenosti glikemije.
Treatment with Xultophy compared to a basal-bolus insulin regimen consisting of basal insulin (insulin glargine 100 units/mL) in combination with bolus insulin (insulin aspart) studied in a 26-week trial in patients with type 2 diabetes mellitus inadequately controlled on insulin glargine and metformin demonstrated a similar reduction of HbA1c in the two groups (mean value from 8.2% to 6.7% in both groups). 
Zdravljenje z zdravilom Xultophy v primerjavi z bazalno-bolusnim insulinskim režimom, ki je vključeval bazalni insulin (insulin glargin 100 enot/ml) v kombinaciji z bolusnim insulinom (insulin aspart), so preučevali v 26-tedenskem preskušanju pri bolnikih z neustrezno nadzorovano sladkorno boleznijo tipa 2 ob zdravljenju z insulinom glargin in metforminom.
1 mL solution contains 100 units insulin degludec* and 3.6 mg liraglutide*. 
En ml raztopine vsebuje 100 enot insulina degludek* in 3,6 mg liraglutida*.
• Change the place within the area where you inject each day to reduce the risk of developing lumps and skin pitting (see section 4). 
Tako boste zmanjšali tveganje za nastanek zatrdlin ali ugreznjenosti kože (glejte poglavje 4).
Transfer from GLP-1 receptor agonist Xultophy 
Prehod z zdravljenja z agonistom receptorjev GLP-1 zdravilo Xultophy agonist receptorjev GLP-1
Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, a component of Xultophy. 
V kliničnih preskušanjih agonistov receptorjev GLP-1, vključno z liraglutidom, ki je sestavina zdravila Xultophy, so poročali o pojavu znakov in simptomov dehidracije, vključno z okvaro ledvic in akutno odpovedjo ledvic.
If you split the dose wrongly, you will inject too little or too much medicine. 
Če je razdeljeni odmerek napačen, lahko injicirate preveč ali premalo zdravila, posledično pa se lahko koncentracija krvnega sladkorja zveča ali zmanjša.
Pancreatitis (including necrotising pancreatitis ) 
napihnjenost trebuha občasni eruktacija, flatulenca neznana pankreatitis (vključno z nekrotizirajočim pankreatitisom)
Each mL of solution contains 100 units of insulin degludec and 3.6 mg liraglutide. 
En ml raztopine vsebuje 100 enot insulina degludek in 3,6 mg liraglutida.
Keep the cap on the pre-filled pen in order to protect from light. 
Napolnjen injekcijski peresnik shranjujte pokrit s pokrovčkom za zagotovitev zaščite pred svetlobo.
This is normal, but you must still check the flow. 
Na konici igle se lahko pojavi kapljica raztopine, kar je normalno, vendar pa morate kljub temu še preveriti pretok.
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 199) for Xultophy and 0.00 (0 patients out of 199) for insulin degludec. 
Delež hude hipoglikemije na bolnikov-let izpostavljenosti (odstotek bolnikov) je bil pri zdravilu Xultophy 0,01 (1 od 199 bolnikov), pri insulinu degludek pa 0,00 (0 od 199 bolnikov).
In the LEADER trial, no long-term clinical impact of increased heart rate on the risk of cardiovascular events was observed with liraglutide (a component of Xultophy) (see section 5.1). 
V preskušanju LEADER z liraglutidom (sestavino zdravila Xultophy) ni bilo opaženega dolgoročnega kliničnega vpliva zvišane frekvence srčnega utripa na tveganje za srčno-žilne dogodke.
Glucose must be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes. 
Če se bolnik na aplikacijo glukagona ne odzove v 10
Insulin degludec and liraglutide exposure increased proportionally with the Xultophy dose within the full dose range based on a population pharmacokinetic analysis. 
Analiza populacijske farmakokinetike kaže, da se izpostavljenost insulinu degludek in liraglutidu povečuje sorazmerno z odmerkom zdravila Xultophy v celotnem obsegu odmerkov.
Transfer of patients from insulin glargine (100 units/mL) to Xultophy or intensification of insulin glargine in patients inadequately controlled on insulin glargine (20-50 units) and metformin were studied in a 26 week trial. 
V 26-tedenskem preskušanju so preučevali prehod na zdravilo Xultophy z zdravljenja z insulinom glargin (100 enot/ml) ali intenziviranje zdravljenja z insulinom glargin pri bolnikih, ki niso bili zadostno urejeni z zdravljenjem z insulinom glargin (20-50 enot) in metforminom.
Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. 
Ko je koncentracija glukoze v krvi velika, se izločanje insulina poveča, izločanje glukagona pa zavre.
• One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide. 
• En odmerni korak vsebuje 1 enoto insulina degludek in 0,036 mg liraglutida.
Instructions on how to use Xultophy 100 units/mL + 3.6 mg/mL solution for injection 
Navodila za uporabo zdravila Xultophy 100 enot/ml + 3,6 mg/ml raztopina za injiciranje
• dehydration (loss of fluids from the body) can happen if you are feeling or being sick (nausea or vomiting) or have diarrhoea - it is important to drink plenty of fluids to stop dehydration. 
• V primeru siljenja na bruhanje, bruhanja ali driske lahko pride do dehidracije (izgube tekočine iz telesa).
• Xultophy is administered as ‘dose steps'. 
• Zdravilo Xultophy se odmerja v “odmernih korakih”.
Low blood sugar may happen if you: 
Prenizek krvni sladkor se lahko pojavi, če:
Dispose of the needle safely after each use. 
Injekcijsko iglo po vsakem injiciranju varno zavrzite.
DEVOTE was a randomised, double-blind, and event-driven clinical trial with a median duration of 2 years comparing the cardiovascular safety of insulin degludec versus insulin glargine (100 units/mL) in 7,637 patients with type 2 diabetes mellitus at high risk of cardiovascular events. 
DEVOTE je bilo randomizirano, dvojno slepo in s številom dogodkov omejeno klinično preskušanje z medianim trajanjem 2 leti, v katerem so primerjali insulin degludek in insulin glargin (100 enot/ml)
Age had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including adult patients up to 83 years treated with Xultophy. 
Podatki analize populacijske farmakokinetike, vključno z bolniki, starimi do 83 let, kažejo, da starost nima klinično pomembnega vpliva na farmakokinetiko zdravila Xultophy.
Liraglutide exposure was decreased by 13-23% in patients with mild to moderate hepatic impairment compared to healthy subjects. 
Pri bolnikih z blago do zmerno okvaro jeter je bila izpostavljenost liraglutidu za 13-23 % manjša kot pri zdravih osebah, pri bolnikih s hudo okvaro jeter (ocena po Child Pughu > 9) pa je bila izpostavljenost pomembno manjša (44 %).
Transfer from GLP-1 receptor agonist 
Prehod z zdravljenja z agonistom receptorjev GLP-1
In addition, constipation, dyspepsia, gastritis, abdominal pain, gastroesophageal reflux disease, abdominal distension, eructation, flatulence and decreased appetite have been reported in up to 3.6% of patients treated with Xultophy. 
3,6 % bolnikov, ki so se zdravili z zdravilom Xultophy, poročali še o zaprtosti, dispepsiji, gastritisu, bolečini v trebuhu, gastroezofagealni refluksni bolezni, napihnjenosti trebuha, eruktaciji, flatulenci in zmanjšanju apetita.
Few cases of anaphylactic reactions with additional symptoms such as hypotension, palpitations, dyspnoea, and oedema have been reported during marketed use of liraglutide. 
Po prihodu liraglutida na trg so poročali o nekaj primerih anafilaktičnih reakcij z dodatnimi simptomi, kot so hipotenzija, palpitacije, dispneja in edem.
• Put the pen cap on your pen after each use to protect the solution from light. 
• Po vsaki uporabi pokrijte injekcijski peresnik s pokrovčkom, da zaščitite raztopino pred svetlobo.
Figure 4 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on insulin glargine 
Slika 4: Povprečna vrednost HbA1c (%) po tednih zdravljenja pri bolnikih z nezadostno urejeno sladkorno boleznijo tipa 2 pri zdravljenju z insulinom glargin
No cardiovascular outcomes trials have been performed with Xultophy. 
• Srčno-žilna varnost Preskušanj srčno-žilnih izidov z zdravilom Xultophy niso izvedli.
The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide. 
Pri sočasni uporabi liraglutida vpliva na učinek kontracepcije ni pričakovati.
Other side effects include: Common (may affect up to 1 in 10 people) 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
Lisinopril median tmax was delayed from 6 h to 8 h with liraglutide. 
Pri uporabi skupaj z liraglutidom se je mediani čas do največje koncentracije (tmax) lizinoprila s 6 ur podaljšal na 8 ur.
Xultophy is administered as dose steps. 
Zdravilo Xultophy se aplicira v odmernih korakih.
You may see a drop of solution at the needle tip after injecting. 
Po injiciranju lahko na konici igle opazite kapljico raztopine.
Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs. 
Če se srčni simptomi kakor koli poslabšajo, je treba zdravljenje s pioglitazonom ukiniti.
The key results of the trial are listed in Figure 1 and Table 3. 
Ključni rezultati preskušanja so prikazani na sliki 1 in v preglednici 3.
If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of 
Če ste pozabili injicirati odmerek, ga injicirajte, ko se na to spomnite, vendar pa morate zagotoviti, da med posameznimi odmerki mine najmanj 8 ur.
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi glicerol fenol cinkov acetat klorovodikova kislina (za uravnavanje pH) natrijev hidroksid (za uravnavanje pH) voda za injekcije
Insulin degludec, maximum 50 units allowed 
insulina degludek pa 50 enot.
Your blood sugar level may fall if you take: 
Koncentracija krvnega sladkorja se lahko zmanjša, če jemljete:
IDegLira obs. rate IDegLira IDeg 
IDegLira op. delež IDegLira
Mean increase in heart rate from baseline of 2 to 3 beats per minute has been observed in clinical trials with Xultophy. 
Srčni utrip se je od izhodišča v povprečju povečal za 2 do 3 utripe na minuto.
One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide. 
En odmerni korak vsebuje 1 enoto insulina degludek in 0,036 mg liraglutida.
You should stop your basal insulin treatment prior to starting on Xultophy. 
Pred začetkom zdravljenja z zdravilom Xultophy morate zdravljenje z bazalnim insulinom prekiniti.
The key results of the trial are listed in Figure 2 and Table 3. 
Ključni rezultati preskušanja so prikazani na sliki 2 in v preglednici 3.
Novo Allé, Bagsværd, 2880, Denmark Name and address of the manufacturer responsible for batch release Novo Nordisk A/S 
Ime in naslov izdelovalca, odgovornega za sproščanje serij Novo Nordisk A/S
3 Select your dose • Turn the dose selector to select the dose you need. 
• Zavrtite izbirnik odmerka, da boste izbrali predpisani odmerek.
Figure 5 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on basal insulin 
Slika 5: Povprečna vrednost HbA1c (%) po tednih zdravljenja pri bolnikih z nezadostno urejeno sladkorno boleznijo tipa 2 pri zdravljenju z bazalnim insulinom
Xultophy 100 units/mL + 3.6 mg/mL solution for injection. 
Xultophy 100 enot/ml + 3,6 mg/ml raztopina za injiciranje
100 units/mL + 3.6 mg/mL, then look at the illustrations below to get to know the different parts of your pen and needle. 
Najprej preverite, če injekcijski peresnik vsebuje zdravilo Xultophy 100 enot/ml + 3,6 mg/ml, nato pa se s pomočjo slik v nadaljevanju seznanite z različnimi deli injekcijskega peresnika in injekcijske igle.
• To see precisely how much solution is left, use the dose counter: 
• Preostalo količino raztopine lahko natančno preverite s pomočjo števca odmerka.
Recommended for use with NovoTwist or NovoFine disposable needles Needles are not included 
POSTOPEK IN POT UPORABE ZDRAVILA Priporočamo uporabo injekcijskih igel NovoTwist ali NovoFine za enkratno uporabo.
It contains 3 mL of Xultophy solution. 
Vsebuje 3 ml raztopine zdravila Xultophy in omogoča odmerjanje:
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.00 (0 patients out of 278) for Xultophy and 0.01 (1 patient out of 279) for insulin glargine. 
Xultophy 0,00 (0 od 278 bolnikov), pri insulinu glargin pa 0,01 (1 od 279 bolnikov).
One dose step contains 1 unit insulin degludec + 0.036 mg liraglutide. 
1 enoto insulina degludek + 0,036 mg liraglutida.
Favours insulin degludec 
Okvara ledvic Insulin degludek
The key results of the trial are listed in Figure 4 and Table 5. 
Ključni rezultati preskušanja so prikazani na sliki 4 in v preglednici 5.
Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000 mg. Paracetamol Cmax was decreased by 31% and median tmax was delayed up to 15 min. No dose adjustment for concomitant use of paracetamol is required. 
Največja koncentracija (Cmax) paracetamola se je zmanjšala za 31 %, mediani čas do največje koncentracije (tmax) pa se je podaljšal za največ 15 minut.
There is no difference in the pharmacokinetics of insulin degludec between healthy subjects and patients with renal impairment. 
Pri bolnikih z okvaro ledvic se farmakokinetika insulina degludek ne razlikuje od farmakokinetike pri zdravih osebah.
Always check the pen label before you inject your medicine to ensure that you use the correct pen. 
Pred vsakim injiciranjem zdravila vedno preverite nalepko na injekcijskem peresniku, da se prepričate,
There is no therapeutic experience in patients with congestive heart failure New York Heart Association (NYHA) class IV and Xultophy is therefore not recommended for use in these patients. 
Association (NYHA) ni, zato uporaba zdravila Xultophy pri teh bolnikih ni priporočljiva.
• Push the needle straight onto the pen. 
• Injekcijsko iglo potisnite naravnost na injekcijski peresnik in jo trdno privijte.
This makes sure that the solution flows. 
To zagotavlja pretok raztopine.
Dose selector Dose button 
3 Izberite odmerek
Dose End of trial Insulin degludec (units) Liraglutide (mg) Estimated difference, insulin degludec dose 
Liraglutid (mg) Ocenjena razlika, odmerek insulina degludek
• Glycaemic control 
• Uravnavanje glikemije
Your blood sugar level may rise if you take: 
Koncentracija krvnega sladkorja se lahko zveča, če jemljete:
3 mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a stopper (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polycarbonate and acrylonitrile butadiene styrene. 
(halobutil/poliizopren) v večodmernem napolnjenem injekcijskem peresniku iz polipropilena, polikarbonata in akrilonitril butadien stirena, ki se ga zavrže.
Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide SC use 
Xultophy 100 enot/ml + 3,6 mg/ml raztopina za injiciranje insulin degludek + liraglutid za s.c. uporabo
Liraglutide stimulates insulin secretion and lowers inappropriately high glucagon secretion in a glucose-dependent manner. 
Liraglutid v odvisnosti od koncentracije glukoze spodbuja izločanje insulina in zmanjšuje neprimerno veliko izločanje glukagona.